Components of the gut microbiome confer immunity against various diseases

GBC-HpVac's new molecule GBC-R1 harnesses the beneficial potential of gastric bacteria while avoiding the risks

A revolution in first-line treatment of allergic diseases is under way

 

GBC-HpVac announces that the lead validation study of its drug candidate has successfully reached its primary endpoint against asthma.

 

GBC-R1 is an immuno-modulatory protein of microbiotic origin that was tested this summer at the respiratory pharmacology department of the renowned Fraunhofer ITEM in Germany. The primary endpoint of this study was the confirmation that the recombinant version of GBC-R1 retains its capacity to improve lung function in a murine model of allergic asthma in a dose-dependent manner. This study also confirms the pertinence of the award-winning academic discovery of the role of this protein against allergic diseases, including allergic asthma, atopic dermatitis and food allergies.

 

“We are very pleased that this validation study has confirmed the activity of GBC-R1 in improving lung function and are proud to once again deliver a project milestone on budget and on time. We look forward to pursuing the lead optimization of our validated lead” says Dr. Jeffrey Shaw, CEO.

 

GBC-HpVac expects that these results will be helpful in finalizing the current series A fundraising, with a first tranche of CHF 3 million and second tranche of CHF 5 million.

GBC-R1

GBC-HpVac SA is addressing one of the most significant unmet needs in human medicine: allergic diseases, in particular asthma, both in adults and in children


GBC-R1 is an immunomodulatory protein with strong epidemiological evidence of activity in humans against asthma and other allergic diseases

Research

In the course of her award-winning studies, Prof. Dr. Anne Müller and her team at the University of Zurich have discovered that GBC-R1 alone has a tolerogenic effect that confers protection against several allergic diseases